Tesamorelin Research: Mechanism and What Published Studies Investigated

What is tesamorelin?

What is tesamorelin? It is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH), stabilised by a trans-3-hexenoic acid group on the N-terminal tyrosine. It is the active molecule in the branded prescription product Egrifta (and the later Egrifta SV) — a factual identification, made without any benefit framing. Its regulatory status is covered in a dedicated section below.

Molecule properties

Tesamorelin is a 44-amino-acid peptide whose defining modification is the N-terminal acylation that confers resistance to dipeptidyl peptidase-4 (DPP-4) relative to native GHRH. It has no cysteine residues — a handling note, since there is no disulfide to scramble — and is supplied lyophilized as tesamorelin acetate. The properties, at a glance:

Structural difference from native GHRH

Native GHRH(1–44) is rapidly cleaved by DPP-4; the N-terminal cap in tesamorelin protects that cleavage site, extending the molecule’s circulating survival. This is a description of chemistry — a stability property — and not an outcome.

Mechanism — the GHRH receptor and the GH/IGF-1 axis

The tesamorelin mechanism characterised in the research literature runs through the GHRH receptor and the downstream GH/IGF-1 axis. Each point is framed as what studies describe:

• It acts as a selective agonist at the GHRH receptor (GHRHR) on anterior-pituitary somatotroph cells.
• Receptor binding triggers a calcium-mediated signalling cascade that leads to synthesis and release of endogenous growth hormone (GH).
• Because it acts upstream at the pituitary — in contrast to exogenous GH — research notes that pulsatile GH secretion is preserved.
• Elevated GH stimulates hepatic IGF-1 synthesis; IGF-1 is the downstream mediator studied in the literature.

The pharmacokinetics reported in research describe a peak plasma level at roughly 15 minutes and a short elimination half-life (about 26–38 minutes), with circulating IGF-1 measurable within 12–24 hours and steady-state IGF-1 reached after around 14 days of daily administration in the studied program (FDA clinical-pharmacology review). These are mechanism and PK descriptions only — no efficacy claim and no dosing translation.

What the published trials investigated

The trial literature is best read in the past tense, as what investigators measured:

• Falutz, Allas et al., NEJM 2007 — a Phase III trial in adults with HIV-associated abdominal fat accumulation; visceral adipose tissue (VAT) measured by CT was the studied endpoint.
• Falutz, Mamputu et al., JCEM 2010 — a pooled analysis of two Phase III trials, with IGF-1, VAT and lipid parameters among the measured variables.
• Stanley, Grinspoon et al., Lancet HIV 2019 — investigated hepatic fat fraction, measured by magnetic resonance spectroscopy, in people with HIV and NAFLD.

The LiverTox/NCBI Bookshelf monograph and review articles (e.g. Falutz, 2011) provide further context. These studies were conducted in specific clinical populations; described accurately, they define a scope of investigation and do not generalise to, or imply, an effect a reader should expect.

Regulatory and investigational status

Stated factually: tesamorelin (Egrifta) received US FDA approval on 10 November 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy, with the later Egrifta SV formulation following. Approval status varies by jurisdiction. Material sold for laboratory research is offered for research use only — it is not the approved medicinal product and is not for human or veterinary use. Nothing here claims that research-grade material is equivalent to, or a substitute for, the approved drug.

In the GHRH / GH-axis research group

Within the GH-axis research group, tesamorelin sits with other secretagogue compounds studied on related but distinct pathways: GHRH analogs (tesamorelin, CJC-1295) act on the GHRH receptor, whereas ghrelin-mimetic secretagogues such as ipamorelin act through a different receptor (GHS-R). Their dedicated research explainers are cross-linked as they ship in this series. This is a research-focus comparison only — no combination or protocol suggestion is made.

Storage and handling (research context)

These are material-handling facts from the stability literature, not a preparation protocol. Lyophilized tesamorelin is reported stable long-term at −20 °C when protected from light; freeze-thaw cycling degrades the powder; and the absence of cysteine simplifies stability because there is no disulfide to scramble. General laboratory reconstitution and handling procedure is covered in the site’s handling reference — this page gives no reconstitution volumes, concentrations, or injection preparation. For interpreting a batch certificate, see how to read a COA.

Research-grade quality and verification

For laboratory research use only, tesamorelin is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, with third-party verification. Check the exact batch on the self-serve verify tool. No potency or efficacy claim is attached.

Frequently asked questions

Literature cited

1. Falutz J, Allas S, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359–2370.
2. Falutz J, Mamputu J-C, et al. Pooled analysis of two Phase III tesamorelin trials. J Clin Endocrinol Metab. 2010.
3. Stanley TL, Grinspoon SK, et al. “Effects of tesamorelin on hepatic fat in HIV-associated NAFLD.” Lancet HIV. 2019;6(12):e821–e830.
4. Falutz J. “Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy” (review; PMC3218714).
5. Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf, NBK548730.
6. EGRIFTA (tesamorelin for injection) — FDA prescribing label, NDA 022505, 2010; CDER Clinical Pharmacology Review (PK / DPP-4 resistance / IGF-1 kinetics; approval 10 Nov 2010).